KilgourMD Raises Series A to Bring Clinical Rigor to Scalp Health and Hair Growth

KilgourMD is not playing in the shallow end of haircare. This is what it looks like when clinical discipline walks into a category that has been coasting on wishful thinking and decides to tighten everything up.

KilgourMD just stepped into its Series A, amount undisclosed, led by Prelude Growth Partners with Willow Growth, Joyance Partners, and Able Partners doubling down. Sacramento is on the board now, whether the rest of the market was paying attention or not. Congratulations to Dr. James Kilgour and Dr. Alok Prasad, COO for turning a category full of guesswork into something that actually reads like medicine instead of marketing.

Dr. James Kilgour did not stumble into this. Cardiff, Oxford, Stanford, then straight into the trenches of dermatology where patients are not looking for vibes, they are looking for results. KilgourMD was built on a simple observation that most of the industry conveniently ignores. If the scalp is aging, the hair does not stand a chance. So instead of selling hope in a bottle, the company built a system that treats the environment where hair either survives or taps out.

The proprietary two step scalp serum system is doing more than sounding good in a pitch. Clinical results show 95% of participants saw decreased shedding in 6 weeks, with meaningful regrowth by 4 months, reviewed by independent dermatologists and accepted into the Journal of Drugs in Dermatology. That is not influencer math. That is receipts.

Meanwhile, the business is not exactly whispering. Profitable in 2025. Thousands of customers nationwide. A bottle moving every 20 seconds. And more than 33% of customers telling someone else to get on board. That is what happens when product market fit stops being a talking point and starts acting like gravity.

Prelude Growth Partners leading this round makes sense. They know when a consumer brand is actually a clinical wedge in disguise. Willow Growth, Joyance Partners, and Able Partners coming back in tells you the early conviction was not a phase, it was pattern recognition.

The play here is not just hair growth. It is category control. Treat scalp aging like skin health, back it with data, and suddenly you are not competing with shampoos, you are building a new lane that looks a lot more like dermatology than beauty.

KilgourMD is not selling miracles. It is selling discipline, data, and a point of view that the market has been avoiding because it requires doing the hard work first. Turns out, the hard work scales just fine.